Evidence map›Paper›PMID 29890679›Full record

ArticleMolecules (Basel, Switzerland)2018

The Design and Synthesis of

Penghui Wang, Lulu Jiang, Yang Cao, Deyong Ye, Lu Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Proteomics Insights into the Gene Network ofAnimals : an open access journal from MDPI · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Penghui WangDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826, Zhangheng Rd., Shanghai 201203, China. wangph@fudan.edu.cn.
Lulu JiangDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826, Zhangheng Rd., Shanghai 201203, China. lljiang16@fudan.edu.cn.
Yang CaoDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826, Zhangheng Rd., Shanghai 201203, China. ycao14@fudan.edu.cn.
Deyong YeDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826, Zhangheng Rd., Shanghai 201203, China. dyye@shmu.edu.cn.
Lu ZhouDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826, Zhangheng Rd., Shanghai 201203, China. zhoulu@fudan.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Upregulation of phosphoglycerate mutase 1 (PGAM1) has been identified as one common phenomenon in a variety of cancers. Inhibition of PGAM1 provides a new promising therapeutic strategy for cancer treatment. Herein, based on our previous work, a series of new

Indexed as

Drug DesignBenzenesulfonamidesCarbon-13 Magnetic Resonance SpectroscopyCell LineCell ProliferationEnzyme InhibitorsHumansPhosphoglycerate MutaseProton Magnetic Resonance SpectroscopySpectrometry, Mass, Electrospray IonizationSulfonamidesXanthonesBenzenesulfonamidesEnzyme InhibitorsPhosphoglycerate Mutasephosphoglycerate mutase 1, humanSulfonamidesXanthonesanti-cancerinhibitorsphosphoglycerate mutase 1xanthone

Identifiers

PMID29890679
PMCPMC6100356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.